Discontinue use in patients w/ clinically significant hypersensitivity; history of hypersensitivity to pegfilgrastim or filgrastim. SJS. Not to be used in myelodysplastic syndrome, chronic myelogenous leukaemia, secondary acute myeloid leukaemia (AML). Long-term effects in AML & De novo
AML patients <55 yr; history of pulmonary infiltrates or pneumonia; glomerulonephritis; sickle cell trait or disease; aortitis. Monitor for pulmonary signs of acute resp distress syndrome; urinalysis. Closely monitor patients who develop capillary leak syndrome. Regularly monitor platelet count, hematocrit & perform WBC count. Mobilisation of blood progenitor cells in patients or healthy donors. Transient +ve bone-imaging findings. Immunogenicity. High-dose & long-term use. Hereditary fructose intolerance. Combination w/ chemotherapeutic agents causing severe thrombocytopenia. Not recommended in women of childbearing potential not using contraception & during pregnancy. Lactation. Childn. Elderly >65 yr.